Plasma Fractionation Market Outlook 2026: Revenue Forecast, Competitive Landscape and Regional Insights

LOS ANGELES, United States: The global Plasma Fractionation market report offers fine intelligence that prepares market players to compete well against their toughest competitors on the basis of growth, sales, and other vital factors. The research study lays emphasis on key growth opportunities and market trends apart from critical market dynamics including market drivers and challenges. With the help of this report, interested parties can equip themselves to adapt according to the changes in the Plasma Fractionation industry and secure a strong market position for years to come. The report provides market development statistics, a list of select leading players, deep regional analysis, and a broad market segmentation study to give a complete understanding of the global Plasma Fractionation market.

The global market for Plasma Fractionation was estimated to be worth US$ 37710 million in 2025 and is projected to reach US$ 62130 million, growing at a CAGR of 7.5% from 2026 to 2032.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart): https://www.qyresearch.in/request-sample/medical-devices-consumables-global-plasma-fractionation-market-insights-industry-share-sales-projections-and-demand-outlook-2026-2032

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation. In this report, we mainly study the Blood Plasma Fractionation products, such as: Immune Globulin, Coagulation Factor, Albumin, etc.

Increasing Demand for Plasma-Derived Therapies: The rising prevalence of chronic diseases, such as immune deficiencies, hemophilia, and autoimmune disorders, has led to increased demand for plasma-derived products like immunoglobulins, clotting factors, and albumin, driving the blood plasma fractionation market.

Aging Population: The global aging population is more prone to chronic diseases and conditions requiring plasma-derived therapies, contributing to the growth of the plasma fractionation market.

Growing Use of Immunoglobulins: Immunoglobulins are increasingly used in the treatment of a wide range of diseases, including primary and secondary immune deficiencies, boosting the need for blood plasma fractionation to produce these therapies.

Rising Healthcare Expenditure and Improved Healthcare Access: Expanding healthcare infrastructure in developing countries, combined with rising healthcare expenditure, is driving demand for advanced medical treatments and plasma-derived products.

High Costs of Plasma-Derived Products: The complex and time-consuming process of plasma fractionation leads to high costs for plasma-derived products, making these treatments less accessible, particularly in low-income regions.

Limited Plasma Supply: The availability of plasma for fractionation is often limited by low donation rates, regulatory restrictions, and the lengthy process of screening and collecting plasma, leading to supply shortages.

Stringent Regulatory Framework: Plasma fractionation is subject to rigorous regulatory requirements to ensure safety and efficacy. Meeting these regulations can increase development costs and slow the introduction of new products to the market.

Complex Manufacturing Process: The plasma fractionation process is technically challenging and requires significant investment in infrastructure, equipment, and skilled labor, posing barriers for new entrants and smaller manufacturers.

The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.

Regional Insights

The report gives a broad explanation about the presence of the Plasma Fractionation market in different regions and countries. With an extensive regional analysis of the Plasma Fractionation market, the research analysts make an attempt to unveil hidden growth prospects available for players in different parts of the world. They accurately estimate market share, CAGR, production, consumption, price, revenue, and other crucial factors that indicate the growth of regional markets studied in the report. They also shed light on the presence of prominent players in regional markets, and how it is making a difference in the growth of the regional markets.

Market Segmentation

Our market analysts are experts in deeply segmenting the global Plasma Fractionation market and thoroughly evaluating the growth potential of each and every segment studied in the report. Right at the beginning of the research study, the segments are compared on the basis of consumption and growth rate for a review period of nine years. The segmentation study included in the report offers a brilliant analysis of the global Plasma Fractionation market, taking into consideration the market potential of different segments studied. It assists market participants to focus on high-growth areas of the global Plasma Fractionation market and plan powerful business tactics to secure a position of strength in the industry.

Segment by Type

Albumin
Immune Globulin
Coagulation Factor
Others

Segment by Indication Mix

PID
Autoimmune
Neuro-immune
Hemophilia
Other

Segment by Plasma Source

Source Plasma
Recovered Plasma

Segment by Application

Hospital
Retail Pharmacy
Other

Competitive Landscape

The report presents a detailed analysis of the competitive landscape along with company profiling of key players competing in the global Plasma Fractionation market. The authors of the report make it a point to provide readers with a complete evaluation of the vendor landscape and inform them about current and future changes therein. The competitive analysis offered in the report includes market share, gross margin, product portfolio, consumption, market status, and technologies of leading players operating in the global Plasma Fractionation market.

Key players profiled in the report on the Global Plasma Fractionation Market are:

Takeda Pharmaceutical Company Limited - Japan
CSL Limited - Australia
Grifols, S.A. - Spain
Octapharma AG - Switzerland
Kedrion S.p.A. - Italy
LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies) - France
Biotest AG - Germany
Bharat Serums and Vaccines Limited (BSV) (formerly BPL - Biological Products Laboratory India operations) - India
RAAS Blood Products, Inc. - China
China Biologic Products Holdings, Inc. (CBPO) - China
Hualan Biological Engineering Inc. - China
China National Biotec Group Company Limited - Tiantan Biological Products Co., Ltd. - China
Shandong Taibang Biological Products Co., Ltd. (Shuanglin Bio) - China
Boya Bio-Pharmaceutical Group Co., Ltd. - China
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - China
Guangdong Weiguang Biological Products Co., Ltd. - China
Guangzhou Nanyue Biological Pharmaceutical Co., Ltd. - China
KM Biologics Co., Ltd. - Japan

How can the research study help your business?

(1) The information presented in the Plasma Fractionation report helps your decision makers to become prudent and make the best business choices.

(2) The report enables you to see the future of the global Plasma Fractionation market and accordingly take decisions that will be in the best interest of your business.

(3) It offers you a forward-looking perspective of the global Plasma Fractionation market drivers and how you can secure significant market gains in the near future.

(4) It provides SWOT analysis of the global Plasma Fractionation market along with useful graphics and detailed statistics providing quick information about the market's overall progress throughout the forecast period.

(5) It also assesses the changing competitive dynamics of the global Plasma Fractionation market using pin-point evaluation.

Request Pre-Order Enquiry or Customized Research On This Report: https://www.qyresearch.in/pre-order-inquiry/medical-devices-consumables-global-plasma-fractionation-market-insights-industry-share-sales-projections-and-demand-outlook-2026-2032

Table of Content

1 Market Overview
1.1 Plasma Fractionation Product Introduction
1.2 Global Plasma Fractionation Market Size Forecast (2021-2032)
1.3 Plasma Fractionation Market Trends & Drivers
1.3.1 Plasma Fractionation Industry Trends
1.3.2 Plasma Fractionation Market Drivers & Opportunities
1.3.3 Plasma Fractionation Market Challenges
1.3.4 Plasma Fractionation Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Plasma Fractionation Players Revenue Ranking (2025)
2.2 Global Plasma Fractionation Revenue by Company (2021-2026)
2.3 Key Companies' R&D and Operations Footprint and Headquarters
2.4 Key Companies Plasma Fractionation Product Offerings
2.5 Key Companies General Availability (GA) Timeline for Plasma Fractionation
2.6 Plasma Fractionation Market Competitive Analysis
2.6.1 Plasma Fractionation Market Concentration Rate (2021-2026)
2.6.2 Top 5 and Top 10 Global Companies by Plasma Fractionation Revenue in 2025
2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Plasma Fractionation revenue, 2025
2.7 Mergers & Acquisitions and Expansion
3 Segmentation Plasma Fractionation Market Classification
3.1 Introduction by Type
3.1.1 Albumin
3.1.2 Immune Globulin
3.1.3 Coagulation Factor
3.1.4 Others
3.1.5 Global Plasma Fractionation Sales Value by Type
3.1.5.1 Global Plasma Fractionation Sales Value by Type (2021 vs 2025 vs 2032)
3.1.5.2 Global Plasma Fractionation Sales Value, by Type (2021-2032)
3.1.5.3 Global Plasma Fractionation Sales Value, by Type (%), 2021-2032
3.2 Introduction by Indication Mix
3.2.1 PID
3.2.2 Autoimmune
3.2.3 Neuro-immune
3.2.4 Hemophilia
3.2.5 Other
3.2.6 Global Plasma Fractionation Sales Value by Indication Mix
3.2.6.1 Global Plasma Fractionation Sales Value by Indication Mix (2021 vs 2025 vs 2032)
3.2.6.2 Global Plasma Fractionation Sales Value, by Indication Mix (2021-2032)
3.2.6.3 Global Plasma Fractionation Sales Value, by Indication Mix (%), 2021-2032
3.3 Introduction by Plasma Source
3.3.1 Source Plasma
3.3.2 Recovered Plasma
3.3.3 Global Plasma Fractionation Sales Value by Plasma Source
3.3.3.1 Global Plasma Fractionation Sales Value by Plasma Source (2021 vs 2025 vs 2032)
3.3.3.2 Global Plasma Fractionation Sales Value, by Plasma Source (2021-2032)
3.3.3.3 Global Plasma Fractionation Sales Value, by Plasma Source (%), 2021-2032
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.1.3 Other
4.2 Global Plasma Fractionation Sales Value by Application
4.2.1 Global Plasma Fractionation Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Plasma Fractionation Sales Value by Application (2021-2032)
4.2.3 Global Plasma Fractionation Sales Value by Application (%), 2021-2032
5 Segmentation by Region
5.1 Global Plasma Fractionation Sales Value by Region
5.1.1 Global Plasma Fractionation Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Plasma Fractionation Sales Value by Region (2021-2026)
5.1.3 Global Plasma Fractionation Sales Value by Region (2027-2032)
5.1.4 Global Plasma Fractionation Sales Value by Region (%), 2021-2032
5.2 North America
5.2.1 North America Plasma Fractionation Sales Value, 2021-2032
5.2.2 North America Plasma Fractionation Sales Value by Country (%), 2025 vs 2032
5.3 Europe
5.3.1 Europe Plasma Fractionation Sales Value, 2021-2032
5.3.2 Europe Plasma Fractionation Sales Value by Country (%), 2025 vs 2032
5.4 Asia Pacific
5.4.1 Asia Pacific Plasma Fractionation Sales Value, 2021-2032
5.4.2 Asia Pacific Plasma Fractionation Sales Value by Subregion (%), 2025 vs 2032
5.5 South America
5.5.1 South America Plasma Fractionation Sales Value, 2021-2032
5.5.2 South America Plasma Fractionation Sales Value by Country (%), 2025 vs 2032
5.6 Middle East & Africa
5.6.1 Middle East & Africa Plasma Fractionation Sales Value, 2021-2032
5.6.2 Middle East & Africa Plasma Fractionation Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Plasma Fractionation Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Plasma Fractionation Sales Value, 2021-2032
6.3 United States
6.3.1 United States Plasma Fractionation Sales Value, 2021-2032
6.3.2 United States Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Plasma Fractionation Sales Value, 2021-2032
6.4.2 Europe Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Plasma Fractionation Sales Value, 2021-2032
6.5.2 China Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.5.3 China Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Plasma Fractionation Sales Value, 2021-2032
6.6.2 Japan Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Plasma Fractionation Sales Value, 2021-2032
6.7.2 South Korea Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Plasma Fractionation Sales Value, 2021-2032
6.8.2 Southeast Asia Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Plasma Fractionation Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Plasma Fractionation Sales Value, 2021-2032
6.9.2 India Plasma Fractionation Sales Value by Type (%), 2025 vs 2032
6.9.3 India Plasma Fractionation Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Takeda
7.1.1 Takeda Profile
7.1.2 Takeda Main Business
7.1.3 Takeda Plasma Fractionation Products, Services, and Solutions
7.1.4 Takeda Plasma Fractionation Revenue (US$ Million), 2021-2026
7.1.5 Takeda Recent Developments
7.2 CSL
7.2.1 CSL Profile
7.2.2 CSL Main Business
7.2.3 CSL Plasma Fractionation Products, Services, and Solutions
7.2.4 CSL Plasma Fractionation Revenue (US$ Million), 2021-2026
7.2.5 CSL Recent Developments
7.3 Grifols
7.3.1 Grifols Profile
7.3.2 Grifols Main Business
7.3.3 Grifols Plasma Fractionation Products, Services, and Solutions
7.3.4 Grifols Plasma Fractionation Revenue (US$ Million), 2021-2026
7.3.5 Grifols Recent Developments
7.4 Octapharma
7.4.1 Octapharma Profile
7.4.2 Octapharma Main Business
7.4.3 Octapharma Plasma Fractionation Products, Services, and Solutions
7.4.4 Octapharma Plasma Fractionation Revenue (US$ Million), 2021-2026
7.4.5 Octapharma Recent Developments
7.5 Kedrion
7.5.1 Kedrion Profile
7.5.2 Kedrion Main Business
7.5.3 Kedrion Plasma Fractionation Products, Services, and Solutions
7.5.4 Kedrion Plasma Fractionation Revenue (US$ Million), 2021-2026
7.5.5 Kedrion Recent Developments
7.6 LFB Group
7.6.1 LFB Group Profile
7.6.2 LFB Group Main Business
7.6.3 LFB Group Plasma Fractionation Products, Services, and Solutions
7.6.4 LFB Group Plasma Fractionation Revenue (US$ Million), 2021-2026
7.6.5 LFB Group Recent Developments
7.7 Biotest
7.7.1 Biotest Profile
7.7.2 Biotest Main Business
7.7.3 Biotest Plasma Fractionation Products, Services, and Solutions
7.7.4 Biotest Plasma Fractionation Revenue (US$ Million), 2021-2026
7.7.5 Biotest Recent Developments
7.8 BPL
7.8.1 BPL Profile
7.8.2 BPL Main Business
7.8.3 BPL Plasma Fractionation Products, Services, and Solutions
7.8.4 BPL Plasma Fractionation Revenue (US$ Million), 2021-2026
7.8.5 BPL Recent Developments
7.9 RAAS
7.9.1 RAAS Profile
7.9.2 RAAS Main Business
7.9.3 RAAS Plasma Fractionation Products, Services, and Solutions
7.9.4 RAAS Plasma Fractionation Revenue (US$ Million), 2021-2026
7.9.5 RAAS Recent Developments
7.10 CBPO
7.10.1 CBPO Profile
7.10.2 CBPO Main Business
7.10.3 CBPO Plasma Fractionation Products, Services, and Solutions
7.10.4 CBPO Plasma Fractionation Revenue (US$ Million), 2021-2026
7.10.5 CBPO Recent Developments
7.11 Hualan Bio
7.11.1 Hualan Bio Profile
7.11.2 Hualan Bio Main Business
7.11.3 Hualan Bio Plasma Fractionation Products, Services, and Solutions
7.11.4 Hualan Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.11.5 Hualan Bio Recent Developments
7.12 Tiantan Bio
7.12.1 Tiantan Bio Profile
7.12.2 Tiantan Bio Main Business
7.12.3 Tiantan Bio Plasma Fractionation Products, Services, and Solutions
7.12.4 Tiantan Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.12.5 Tiantan Bio Recent Developments
7.13 Shuanglin Bio
7.13.1 Shuanglin Bio Profile
7.13.2 Shuanglin Bio Main Business
7.13.3 Shuanglin Bio Plasma Fractionation Products, Services, and Solutions
7.13.4 Shuanglin Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.13.5 Shuanglin Bio Recent Developments
7.14 Boya Bio
7.14.1 Boya Bio Profile
7.14.2 Boya Bio Main Business
7.14.3 Boya Bio Plasma Fractionation Products, Services, and Solutions
7.14.4 Boya Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.14.5 Boya Bio Recent Developments
7.15 Yuanda Shuyang
7.15.1 Yuanda Shuyang Profile
7.15.2 Yuanda Shuyang Main Business
7.15.3 Yuanda Shuyang Plasma Fractionation Products, Services, and Solutions
7.15.4 Yuanda Shuyang Plasma Fractionation Revenue (US$ Million), 2021-2026
7.15.5 Yuanda Shuyang Recent Developments
7.16 Weiguang Bio
7.16.1 Weiguang Bio Profile
7.16.2 Weiguang Bio Main Business
7.16.3 Weiguang Bio Plasma Fractionation Products, Services, and Solutions
7.16.4 Weiguang Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.16.5 Weiguang Bio Recent Developments
7.17 Nanyue Bio
7.17.1 Nanyue Bio Profile
7.17.2 Nanyue Bio Main Business
7.17.3 Nanyue Bio Plasma Fractionation Products, Services, and Solutions
7.17.4 Nanyue Bio Plasma Fractionation Revenue (US$ Million), 2021-2026
7.17.5 Nanyue Bio Recent Developments
7.18 KM Biologics
7.18.1 KM Biologics Profile
7.18.2 KM Biologics Main Business
7.18.3 KM Biologics Plasma Fractionation Products, Services, and Solutions
7.18.4 KM Biologics Plasma Fractionation Revenue (US$ Million), 2021-2026
7.18.5 KM Biologics Recent Developments
8 Industry Chain Analysis
8.1 Plasma Fractionation Value Chain
8.2 Plasma Fractionation Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Cost Structure
8.3 Midstream Analysis
8.4 Downstream (Customer) Analysis
8.5 Sales Model and Sales Channelss
8.5.1 Plasma Fractionation Sales Model
8.5.2 Sales Channels
8.5.3 Plasma Fractionation Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 18 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

Contact US

QY Research, INC.
17890 Castleton Street Suite 369
City of Industry, CA, 91748
United States
Email: ankit@qyresearch.com | Tel: +1 626 295 2442
Website: https://www.qyresearch.com

This release was published on openPR.